Data that meets regulatory and scientific standards for decision-making
Celbridge Science applies advanced in silico analytics to preclinical and translational data to improve decision-making, reduce unnecessary animal testing, and deliver regulatory-ready insights across drug development and biomedical research.
We partner with research organizations, biotech firms, and government-funded programs to transform complex biological data into transparent, traceable, and decision-grade evidence—supporting faster, more ethical, and more cost-effective development pathways.
At a Glance
InSilicon™ Analytics
InSilicon™
Analytics Platform
InSilicon™ Analytics is Celbridge Science’s in silico modeling and decision-support platform for evaluating preclinical and translational data at scale.
- Identify redundant or low-value animal studies before execution
- Prioritize compounds and study designs based on predicted signal strength
- Generate traceable, regulator-aligned evidence for review and submission
- Model biological response pathways and comparative outcomes
InSilicon™
Strategy & Implementation
Celbridge Science supports organizations across the full analytics lifecycle—from assessment through execution.
- Portfolio assessment and opportunity sizing
- In silico hypothesis testing and scenario evaluation
- Decision prioritization aligned to regulatory and ethical standards
- Implementation guidance for reduced animal use and optimized study design
How We Work
Assess
Review animal testing portfolios, data readiness, and regulatory constraints.
Model
Apply in silico models to assess alternatives and non-inferiority potential.
Prioritize
Deliver a transition roadmap with time, cost, and animal-use estimates.
Implement & Validate
Run pilots, produce regulator-ready documentation, and improve models continuously.
Measurable Impact
What You Gain
Ethical & Reputational Leadership
Measurably reduce animal use and align with stakeholder values
Cost & Cycle Time Reduction
Fewer redundant in vivo studies, faster go/no-go decisions, smarter portfolio allocation.
Regulatory-Ready Evidence
Government-funded science and traceable models to support engagement with regulators.
Who We Work With
Pharma and biotech portfolios
Identify toxicology and exploratory studies that can transition to in silico models.
CRO service expansion
Add AI-based non-animal options to the current in vivo testing menu.
Regulatory and policy pilots
Support national or institutional initiatives to reduce animal use with robust analytics.
Academic and translational research
Design grant proposals and programs centered on validated in silico approaches.
Insights
How AI is Driving The Future of Autonomous Systems
How AI is Driving The Future of Autonomous Systems
How AI is Driving The Future of Autonomous Systems
A New Way to Accelerate Your AI Plans
A New Way to Accelerate Your AI Plans
A New Way to Accelerate Your AI Plans
How data AI and automation can transform the enterprise
How data AI and automation can transform the enterprise
How data AI and automation can transform the enterprise
